Keywords: Merck & Co, Johnson & Johnson, Remicade, Simponit, Marketing rights, Rheumatoid arthritis, M&A, Synthes, Devices

Merck & Co and Johnson & Johnson settle long-running battle over Remicade and Simponi marketing; J&J eyeing Swiss acquisition

Article | 18 April 2011

Print This

US drug majors Merck & Co) and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc have ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in